Cannabis Co-Use and Endocannabinoid System Modulation in Tobacco Use Disorder: A Translational Systematic Review and Meta-Analysis
| Journal | medRxiv: the preprint server for health sciences |
| Study Type | Systematic Review |
| Population | Human participants |
With cannabis legalization expanding and nearly one in five tobacco users also using cannabis, clinicians need evidence-based guidance on how co-use affects smoking cessation success. This comprehensive review addresses a critical knowledge gap as we manage patients with dual substance use patterns.
This systematic review and meta-analysis examined 52 studies across observational, preclinical, and human experimental designs to understand cannabis co-use impacts on tobacco cessation and endocannabinoid system therapeutic potential. Meta-analysis of 18 observational studies involving over 229,000 participants found that cannabis use was associated with reduced tobacco cessation success rates. The review synthesized evidence from multiple study types to provide a translational perspective on endocannabinoid system modulation for tobacco use disorder, where current pharmacotherapies achieve less than 30% twelve-month abstinence rates.
“This confirms what I observe clinically – patients using both cannabis and tobacco face additional complexity in cessation efforts. While the endocannabinoid system remains an intriguing therapeutic target, the current evidence suggests cannabis co-use may complicate rather than facilitate tobacco cessation.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
Does using cannabis make it harder to quit smoking tobacco?
It appears to be linked to lower success. A meta-analysis of 18 observational studies involving more than 229,000 participants found that cannabis use was associated with reduced tobacco cessation success rates. The review reports this as an association drawn from observational studies.
What kinds of studies were included in this review?
The review examined 52 studies spanning observational, preclinical, and human experimental designs. It aimed to understand how cannabis co-use affects tobacco cessation and whether the endocannabinoid system has therapeutic potential. It was posted on medRxiv, a preprint server for health sciences.
How effective are current medications for tobacco use disorder?
According to the review, current pharmacotherapies for tobacco use disorder achieve twelve-month abstinence rates below 30%. Put another way, fewer than three in ten people treated with existing medications are still abstinent a year later, based on the figure the review reports.
Does the review suggest the endocannabinoid system could help treat tobacco addiction?
The review considered that question. It synthesized evidence from multiple study types to offer a translational perspective on endocannabinoid system modulation for tobacco use disorder. However, the summary does not report specific findings on whether targeting this system improves quit rates, so no conclusion about effectiveness can be drawn from it.
